Jaktinib clinical trials
Includes 1 study of Jaktinib dihydrochloride monohydrate.
How each study uses jaktinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the jaktinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 8
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (32) · Nanfang Hospital, Southern Medical University (2) · Ruijin Hospital (2) · Peking Union Medical College Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Yujun DONG (1) · First Affiliated Hospital of Zhejiang University (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test jaktinib.
- Feb 2027A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.Phase 1 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Feb 2027Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line TherapyPhase 2 · Ruijin Hospital
- Feb 2027Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior TherapyPhase 1/2 · Yujun DONG
- Apr 2027Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Apr 2027Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaPhase 1/2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Jun 2027Jaktinib for Steroid-Refractory Acute Graft-Versus-Host DiseasePhase 1/2 · Nanfang Hospital, Southern Medical University
- Nov 2027Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).Phase 1/2 · Institute of Hematology & Blood Diseases Hospital, China
Studies
Open first, then newest update. How each study uses jaktinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 40
- Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and AnemiaNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07938580Written as Gecacitinib
- An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell TransplantationRecruitingPhase 1/2Ruijin HospitalNCT07883382Written as gecacitinib Hydrochloride Tablets
- Jaktinib for Steroid-Refractory Acute Graft-Versus-Host DiseaseNot yet recruitingPhase 1/2Nanfang Hospital, Southern Medical UniversityNCT07885228Written as Jaktinib
- Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).Not yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07476872Written as Gecacitinib
- Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With MyelofibrosisNot yet recruitingNot applicableNanfang Hospital, Southern Medical UniversityNCT07440654Written as Gecacitinib
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06903377Written as Gecacitinib Hydrochloride Tablets
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06883526Written as Gecacitinib Hydrochloride Tablets
- Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line TherapyNot yet recruitingPhase 2Ruijin HospitalNCT07197112Written as Gecacitinib
- Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior TherapyRecruitingPhase 1/2Yujun DONGNCT07012304Written as Gecacitinib Hydrochloride Tablets
- A Safety and Tolerability Study of JaktinibRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05279001Written as Jaktinib Hydrochloride Tablet
- A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.Not yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04971551Written as Jaktinib Hydrochloride Tablets
- An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05686629Written as Jaktinib hydrochloride tablets
- A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05688839Written as Jaktinib hydrochloride tablets
- A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisCompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05526222Written as Jaktinib Hydrochloride Tablet
- A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisCompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05676242Written as Jaktinib Hydrochloride Tablet
- Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)CompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05861128Written as Jaktinib
- Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)CompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05861102Written as Jaktinib
- A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.Active, not recruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07565597Written as Gecacitinib Hydrochloride Tablets
- Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05255237Written as Jaktinib
- Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05051761Written as Jaktinib
See all 40 studies that test jaktinib →
Given beside what is tested · 3 — jaktinib is usual care or a partner of the new treatment
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07454226Written as Gecacitinib
- Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07080216Written as Gecacitinib
- Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsNot yet recruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07142837Written as Gecacitinib
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered3
- Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and AnemiaNov 16, 2026NCT07938580
- Jaktinib for Steroid-Refractory Acute Graft-Versus-Host DiseaseOct 21, 2026NCT07885228
- An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell TransplantationOct 20, 2026NCT07883382